1,854 reports of this reaction
2.9% of all BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE reports
#15 most reported adverse reaction
OSTEOPENIA is the #15 most commonly reported adverse reaction for BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE, manufactured by Gilead Sciences, Inc.. There are 1,854 FDA adverse event reports linking BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE to OSTEOPENIA. This represents approximately 2.9% of all 62,897 adverse event reports for this drug.
BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE has an overall safety score of 85 out of 100. Patients taking BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE who experience osteopenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OSTEOPENIA is a less commonly reported adverse event for BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE, but still significant enough to appear in the safety profile.
In addition to osteopenia, the following adverse reactions have been reported for BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE:
The following drugs have also been linked to osteopenia in FDA adverse event reports:
OSTEOPENIA has been reported as an adverse event in 1,854 FDA reports for BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
OSTEOPENIA accounts for approximately 2.9% of all adverse event reports for BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE, making it a notable side effect.
If you experience osteopenia while taking BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.